Physician profile
Carrie E Tyner
NPI 1114357613
$2,324.15
in general payments reported to CMS, 2019-2025
19 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $717 · 2023: $885 · 2024: $583 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $494.63 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $371.07 | 2022-2025 | |
| Lilly USA, LLC | $337.23 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $277.73 | 2022-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $261.07 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $101.81 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $94.42 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $74.78 | 2022-2025 | |
| Amgen INC. | $68.03 | 2022-2025 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $51.82 | 2022 | |
| Dexcom, INC. | $33.63 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $32.43 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $27.21 | 2024 | |
| Idorsia Pharmaceuticals US INC | $21.23 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $18.60 | 2023 | Aptima, Third Wave, Thinprep 2000 Processor |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $17.69 | 2024 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.76 | 2023 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Tyner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.